irsogladine has been researched along with Behcet Syndrome in 1 studies
irsogladine: RN given refers to parent cpd; MN 1695 refers to maleate salt
Behcet Syndrome: Rare chronic inflammatory disease involving the small blood vessels. It is of unknown etiology and characterized by mucocutaneous ulceration in the mouth and genital region and uveitis with hypopyon. The neuro-ocular form may cause blindness and death. SYNOVITIS; THROMBOPHLEBITIS; gastrointestinal ulcerations; RETINAL VASCULITIS; and OPTIC ATROPHY may occur as well.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Irsogladine 2-4 mg/day was administered orally to ten BD patients (cases 1-10), three men and seven women, with a mean age of 48." | 2.73 | Irsogladine is effective for recurrent oral ulcers in patients with Behçet's disease : an open-label, single-centre study. ( Kamatani, N; Kotake, S; Nanke, Y; Ogiuchi, H; Okamoto, T, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nanke, Y | 1 |
| Kamatani, N | 1 |
| Okamoto, T | 1 |
| Ogiuchi, H | 1 |
| Kotake, S | 1 |
1 trial available for irsogladine and Behcet Syndrome
| Article | Year |
|---|---|
Irsogladine is effective for recurrent oral ulcers in patients with Behçet's disease : an open-label, single-centre study.
Topics: Administration, Oral; Adult; Anti-Ulcer Agents; Behcet Syndrome; Cell Communication; Female; Follow- | 2008 |